RCS - Ondine Biomedical - Burnaby Hospital deploys Steriwave

Ondine BiomedicalAnnouncement

29/09/2023 09:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230929:nRSc0777Oa&default-theme=true

RNS Number : 0777O  Ondine Biomedical Inc.  29 September 2023

29 September 2023

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Burnaby Hospital deploys Steriwave

Burnaby Hospital in British Columbia has deployed Steriwave nasal
photodisinfection to help prevent surgical site infections and optimize
patient outcomes

Burnaby Hospital, a large community hospital in British Columbia, has
initiated use of Ondine Biomedical's (OBI:LON) Steriwave® nasal
photodisinfection prior to orthopedic surgery to further reduce the incidence
of post-surgical infections. Burnaby Hospital, which is affiliated with the
University of British Columbia and an integral part of the Fraser Health
Authority, has been focused on further reducing infections and optimizing
patient outcomes following orthopedic surgery.

Post-surgical infections are a serious concern in the aftermath of any major
surgical operation, including orthopedic surgeries. These infections are often
correlated with adverse outcomes including prolonged hospital stays, escalated
healthcare expenses, and elevated mortality rates.

During 2023 there has been a significant rise in Canadian hospitals deploying
Steriwave nasal photodisinfection to reduce the incidence of post-surgical
infections, improve patient care, and reduce costs. The Society for Healthcare
Epidemiology of America (SHEA) updated guidelines, published in May 2023,
recommend nasal decolonization for major surgical procedures which has
encouraged more hospitals to adopt it as a standard practice.( 1  (#_edn1) )

There is a growing concern over using the antibiotic mupirocin for nasal
decolonization, which has been the standard of care but has resistance rates
reported as high as 81%.( 2  (#_edn2) ) Steriwave nasal photodisinfection is
non-antibiotic and kills all types of pathogens - viruses, bacteria, and fungi
- in minutes without causing antimicrobial resistance (AMR).

Carolyn Cross CEO said:

"As a Canadian company pioneering this photodisinfection technology, it is
fantastic to see more and more Canadian hospitals recognizing the importance
of decolonizing pathogens in the nose to prevent post-surgical infections, and
the need to do so without the use of antibiotics. We are very pleased to be
working with the team at Burnaby Hospital who have initiated the use of our
Steriwave nasal decolonization therapy to further enhance patient outcomes."

Pre-surgical use of Steriwave in hospital settings has resulted in significant
improvements in post-surgical outcomes including lower rates of surgical site
infections (SSIs), reduced patient length of stay, fewer readmissions, and
lower rates of antibiotic prescribing.( 3  (#_edn3) )(,( 4  (#_edn4) )),( 5 
(#_edn5) )

Ondine's nasal photodisinfection is already in use in or under evaluation at
other major hospitals across Canada, including Vancouver General Hospital, The
Ottawa Hospital, and the Montreal Heart Institute.

 

**ENDS**

 

 Ondine Biomedical Inc.
 Carolyn Cross, CEO                                           +001 (604) 665 0555

 Singer Capital Markets (Nominated Adviser and Joint Broker)
 Aubrey Powell, Asha Chotai, Sam Butcher                      +44 (0)20 7496 3000

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan                               +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                             +44 (0)77 1000 5910

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the
field of photodisinfection therapies. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection platform, in various
stages of development. Products beyond nasal photodisinfection include
therapies for a variety of medical indications such as chronic sinusitis,
ventilator-associated pneumonia, burns, and other indications.

About Nasal Photodisinfection

Ondine's nasal photodisinfection is a patented technology using a proprietary
photosensitizer (non- antibiotic, light-activated agent) to destroy pathogens.
The photodisinfection treatment is carried out by a trained healthcare
professional and is an easy to use, painless, two-step process. The
photosensitizer is applied to each nostril using a nasal swab, followed by
illumination of the area with a specific wavelength of red laser light for
less than five minutes. The light activates the photosensitizer, causing an
oxidative burst that is lethal to all types of pathogens. A key benefit of
this approach, unlike with antibiotics, is that pathogens do not develop
resistance to the therapy.

Nasal decolonization with antibiotics is already standard practice in many
hospitals prior to surgery, as pathogens in a patient's nasal cavities are a
major cause of surgical site infections (SSIs). However, there is a growing
need to reduce antibiotic use and find non-antibiotic methods of nasal
decolonization as resistance rates have been reported as high as 81%.( 6 
(#_edn6) )

Ondine's nasal photodisinfection system has a CE mark in Europe and the UK and
is approved in Canada and several other countries under the name Steriwave®.
It has been used in Canada for over ten years, with no serious adverse events
reported. In the US, it is currently undergoing clinical trials for regulatory
approval.

About Burnaby Hospital

Burnaby Hospital, with 286 beds and approximately 84,000 patient visits
annually, is one of the largest hospitals in the region outside the City of
Vancouver. It is operated by the Fraser Health Authority-which manages 11
hospitals in the region-and is affiliated with the University of British
Columbia. Serving the communities of Burnaby and East Vancouver as a primary
and secondary care centre, the hospital provides general surgery, orthopedic
surgery, medicine, perinatal, neonatal ICU, critical care and emergency
services.

 1  (#_ednref1) Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to
prevent surgical site infections in acute-care hospitals: 2022 Update. Infect
Control Hosp Epidemiol. 2023;44(5):695-720. doi:10.1017/ice.2023.67

 2  (#_ednref2) Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance:
clinical implications and potential alternatives for the eradication of
MRSA. J Antimicrob Chemother. 2015;70(10):2681-2692. doi:10.1093/jac/dkv169

 3  (#_ednref3) Banaszek D, Inglis T, Tamir Ailon T, Charest-Morin R, Dea N,
Fisher C, Kwon B, Paquette S, Street J. The efficacy and cost-effectiveness of
photodynamic therapy in prevention of surgical site infection. The Spine
Journal, Volume 19, Issue 9, Supplement, 2019, Page S138.

 4  (#_ednref4)
https://www.londonstockexchange.com/news-article/OBI/ottawa-hospital-presents-steriwave-study-
results/15860312
(https://www.londonstockexchange.com/news-article/OBI/ottawa-hospital-presents-steriwave-study-%20results/15860312)

 5  (#_ednref5) Bryce E, Wong T, Forrester L, et al. Nasal photodisinfection
and chlorhexidine wipes decrease surgical site infections: a historical
control study and propensity analysis [published correction appears in J Hosp
Infect. 2015 Sep;91(1):93]. J Hosp Infect. 2014;88(2):89-95.
doi:10.1016/j.jhin.2014.06.017

 6  (#_ednref6) Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance:
clinical implications and potential alternatives for the eradication of
MRSA. J Antimicrob Chemother. 2015;70(10):2681-2692. doi:10.1093/jac/dkv169

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUWAWROBUKUAR